1. Evaluation of the effects of vitamin D analogs, bevacizumab, and radiotherapy in uveal melanoma cells.
- Author
-
Akgun Z, Dogan E, Degirmenci C, Ozkaya Akagunduz O, Esassolak M, Bozok V, and Palamar M
- Subjects
- Humans, Blotting, Western, Angiogenesis Inhibitors pharmacology, Cell Line, Tumor, Cell Cycle drug effects, Tumor Cells, Cultured, Vascular Endothelial Growth Factor A metabolism, Vitamin D analogs & derivatives, Vitamin D pharmacology, Uveal Neoplasms radiotherapy, Uveal Neoplasms drug therapy, Uveal Neoplasms pathology, Uveal Neoplasms metabolism, Melanoma drug therapy, Melanoma pathology, Melanoma radiotherapy, Bevacizumab pharmacology, Apoptosis drug effects, Cell Proliferation drug effects, Cell Survival drug effects
- Abstract
Due to the lack of a definitive effective treatment method that provides a complete cure and increases survival rates in uveal melanoma, the search for alternative treatments at the molecular level continues. In this context, we aimed to comparatively analyze the therapeutic effects of 25-hydroxyvitamin D3 (D2), 1a, 25-dihydroxyvitamin D3 (D3), bevacizumab and radiotherapy (RT) in a uveal melanoma cell line (MP41). Cytotoxicity was evaluated using XTT cell proliferation kit and Xcelligence cell analyzer system. RT dose was determined after a clonogenic assay. Annexin V/PI staining and Western blot analyses for caspase-3, -8, and -9 were performed to analyze apoptosis. Additionally, cell cycle analyses were also conducted. As a result, we found that D2 and D3 did not show cytotoxic effects, while bevacizumab and RT showed time and dose-dependent cytotoxicity. IC
50 concentration of bevacizumab was 6.945 mg/mL. Radiotherapy and bevacizumab significantly reduced cell survival and induced apoptosis when administered both as monotherapy and in combination. A significant increase in caspase proteins was detected at high bevacizumab concentrations. However, the combination of bevacizumab and radiotherapy caused a substantial decrease in caspase-3, -8 and -9 expressions. No significant difference in cell cycle distribution was detected in any treatment. Our results showed that bevacizumab inhibited MP41 cell proliferation and had an additive effect when administered with RT. In conclusion, our study offers a different perspective on the treatment of uveal melanoma, and these results, when supported by animal experiments and clinical studies in the future, might be a new step in the treatment of this challenging ocular tumor., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF